Intervention

BG00012

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions4

Lead sponsors shown1

Clinical trials

5 shown

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MSNCT00837785 · 2009-02-28

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid ArthritisNCT00810836 · 2008-12-01

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisNCT00451451 · 2007-06-01

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple SclerosisNCT00420212 · 2007-01-01

Efficacy and Safety of BG00012 in MSNCT00168701 · 2004-10-01

Common conditions

Relapsing-Remitting Multiple Sclerosis2 Multiple Sclerosis1 Relapsing Remitting Multiple Sclerosis1 Rheumatoid Arthritis1

Leading sponsors

Trial status mix

COMPLETED5

Phase mix

PHASE22

PHASE32

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.